Business Wire

Kuwait’s ‘Visionary Lighthouse’ Pavilion Illuminates Expo 2025 Osaka with Innovative Design and a Future-Driven Vision

Share

The Kuwait Pavilion at Expo 2025 Osaka, Kansai, Japan, officially opened its doors today, unveiling a spectacular architectural landmark that embodies the country’s bold vision for the future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422295094/en/

The Kuwait Pavilion at Expo 2025 Osaka (Photo: AETOSWire)

Designed as a “Visionary Lighthouse”, the pavilion stands as a dynamic symbol of the ambitious national development plan, New Kuwait 2035, seamlessly integrating the nation’s rich heritage, innovation, and sustainability in a transformative visitor experience that engages audiences from around the world.

Located in the “Empowering Lives” district, the pavilion’s design draws inspiration from Kuwait’s maritime and desert landscapes, reflecting the nation’s journey of resilience, progress, and forward-looking spirit.

Kuwait’s participation in Expo 2025 Osaka highlights the continuation of a long-standing relationship between Kuwait and Japan, built on economic collaboration, cultural exchange, and mutual respect. Having first participated in Expo Osaka in 1970, Kuwait returns 55 years later with a pavilion that emphasises the country’s expanding influence in regional and international development.

Salem Al-Watyan, Commissioner General of the State of Kuwait Pavilion at Expo 2025 Osaka, said: "Our presence at Expo 2025 Osaka is a testament to Kuwait’s enduring friendship with Japan. The pavilion reflects our rich heritage and our commitment to shaping a sustainable and innovative future, highlighting Kuwait’s vision as a leader in global collaboration."

Dr. Naser Al Daihani, Director of the State of Kuwait Pavilion at Expo 2025 Osaka, said: "This pavilion captures Kuwait’s ambition and resilience, offering visitors a unique journey connecting the past and the future. As we celebrate our participation in this global event, we look forward to fostering new partnerships and further enhancing Kuwait’s global presence and influence."

Complementing the architecture, the pavilion’s visual identity draws from the natural elements of Kuwait.

The pavilion’s interactive and immersive interior invites visitors on a multi-sensory journey through Kuwait’s rich past and its bold aspirations for a sustainable, innovative, and technology-driven future. Through storytelling and exhibits, the experience highlights Kuwait’s commitment to empowering lives through progress, knowledge, and collaboration.

The Pavilion's bold, open design blends seamlessly into the public realm while making a strong visual impact.

The pavilion’s inauguration featured the spectacular Pearl Lighting Show, an evocative tribute to Kuwait’s maritime heritage and future aspirations.

The Kuwait Pavilion promises to be one of the most compelling attractions at Expo 2025 Osaka.

Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422295094/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye